placebo + pioglitazone

placebo + pioglitazone refers to a specific treatment arm used as a comparator in clinical trials conducted by Boehringer Ingelheim, notably in the evaluation of linagliptin as an initial combination therapy. This arm consists of the active drug pioglitazone, a thiazolidinedione, administered alongside a placebo that matches the active DPP-4 inhibitor (linagliptin) to ensure a double-blind study design. Pioglitazone functions as a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a nuclear receptor that regulates the expression of genes involved in glucose and lipid metabolism. By activating PPAR-gamma, pioglitazone increases insulin sensitivity in the liver, adipose tissue, and skeletal muscle, leading to improved glycemic control and reduced HbA1c levels in patients with type 2 diabetes mellitus.

Other names

pioglitazone + placebopioglitazone monotherapy arm